Earendil Labs raised $787 million in an investment round led by Dimension Capital, DST Global and Sanofi to develop biologics.[1] The funding will enable the AI-powered drug discovery platform to be extended across the biologics development cycle.[1] The company plans to strengthen its teams of scientists, engineers and translation experts to support its growing drug portfolio.[1] In 2025, Sanofi granted an exclusive worldwide license to two bispecific antibodies HXN-1002 for ulcerative colitis and Crohn's disease and HXN-1003 for colitis and dermatitis, with an upfront payment of $125 million and the potential for up to $1.72 billion in milestones.[1][4] In 2026, it entered into another collaboration with Sanofi on bispecific antibodies for autoimmune and inflammatory diseases, with upfront and near-term payments of $160 million and a total potential of $2.56 billion, including royalties in the low double-digit percentages.[2][3] The Earendil Labs platform combines predictive protein modeling with high-throughput experimental validation to identify and optimize candidates.[2][3] Cooperation with Sanofi confirms the company's ability to generate high-quality biologicals headed for clinical trials.[1] The funding will support the advancement of internal programs to clinical milestones and new global partnerships.[1]